Providing critical insights as a first-in-class diagnostic blood test for axial spondyloarthritis.
What is Axial Spondyloarthritis?
Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac joints, causing pain, stiffness and joint damage.
Burden of Diagnostic Delay
AxSpA imposes a significant burden on patients, impacting physical function, mental health, and work productivity. Diagnosis is often delayed by 7-10 years due to the absence of reliable biomarkers, with many cases misdiagnosed as chronic low back pain. Early detection is critical for preventing long-term damage and improving patient outcomes.1
Key Benefits of SPINEstat® (Anti-14-3-3eta Multiplex)
Addresses the back pain challenge
Differentiates axSpA from mechanical causes.
Supports earlier intervention
Identifies patients who need referral and treatment sooner.
Complements existing tools
Combines CRP, HLA-B27, and imaging to increase confidence.
Improved Outcomes
Helps reduce the 7-10 year diagnostic delay and risk of spinal damage.
Addressing critical gaps in the axSpA patient journey
SPINEstat® (Anti-14-3-3eta Multiplex) is a first-in-class diagnostic blood test that aims to eliminate diagnostic delays throughout the continuum of patient care for axSpA.
What is SPINEstat® (Anti-14-3-3eta Multiplex)?
SPINEstat® (Anti-14-3-3eta Multiplex) measures five autoantibodies to 14-3-3eta, a normally intracellular protein associated with autoimmune rheumatologic disorders. The test provides a single risk score that indicates an individual’s likelihood of having axSpA and helps distinguish inflammatory from mechanical back pain.
At a glance
Simple blood test designed for routine clinical use
Multiplex immunoassay measuring 5 analytes
Single score readout for straightforward interpretation
SPINEstat® (Anti-14-3-3eta Multiplex) performance highlights
90% specificity | reliable exclusion of non-axSpA
Diagnostic Odds Ratio up to 63.7 | confirms powerful discrimination
Positive Predictive Value up to 95% | exceeds referral benchmarks
SPINEstat® (Anti-14-3-3eta Multiplex) adds powerful biomarker insight to the axSpA diagnostic pathway, helping clinicians detect disease earlier and guide timely intervention.
SPINEstat® (Anti-14-3-3eta Multiplex) complements existing markers and aids in the early and accurate diagnosis of axSpA.
Differentiates axSpA from Mechanical Back Pain
Distinguishes inflammatory from mechanical back pain, helping identify axSpA earlier.3
High Specificity and Sensitivity
Maintains high specificity for accurate identification and improved sensitivity when combined with standard clinical markers.3
Complements Existing Markers
Improves diagnostic accuracy and increases positive predictive value when used with CRP and HLA-B27.3
Strong Diagnostic Odds Ratio
Significantly increase in diagnostic odds ratio, especially when combined with existing markers.3
SPINEstat® (Anti-14-3-3eta Multiplex) advances early detection of axSpA and supports faster referral for timely treatment.
Nationwide availability coming in 2026. For more information, download the brochure below.
Learn more about SPINEstat® for axSpA
Explore detailed study data, assay performance, and clinical insights that highlight how SPINEstat supports earlier and more accurate diagnosis of axial spondyloarthritis.
References
References:
- Poddubnyy D, Garrido-Cumbrera M, Sommerfleck F, et al. POS0689. Diagnostic delay in patients included in the International Map of Axial Spondyloarthritis: associations with geographic, socio-demographic and disease-related factors. Annals of the Rheumatic Diseases. 2023;82:628-629
- The burden of axial spondyloarthritis: A global patient perspective. International Map of Axial Spondyloarthritis (IMAS) Report. 2024, Jan. https://asif.info/imas/imas-global-report
- Sengupta R, Marotta A, Maksymowych WP, Cavill C, Bleakley S, Biln N. Autoantibodies to 14-3-3eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis. Presented at: American College of Rheumatology (ACR) Convergence 2025; October 2025; Chicago, IL. Oral Presentation. Abstract 2636.
